Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
TransCode Therapeutics (NASDAQ: RNAZ) will be featured in a free investor webinar hosted by RedChip Companies on Wednesday, September 16, 2026, at 4:15 p.m. ET, with Chairman and CEO Philippe P. Calais, co-founder and CSO Zdravka Medarova, and CFO Tom Fitzgerald presenting. Management will recap TTX-MC138, the lead RNA therapeutic targeting microRNA-10b: the completed Phase 1a trial met its safety endpoint with no dose-limiting toxicities, and 64% of evaluable patients achieved stable disease.
Key figures
- Drug Name
- TTX-MC138
- Phase Of Trial
- Phase 2a
- Additional readouts
- Phase 2a and Phase 1a readouts expected through 2027
- Phase 2a population
- ctDNA-positive colorectal cancer patients with minimal residual disease
- Seviprotimut L status
- Phase 3 melanoma vaccine with FDA Fast Track and Orphan Drug designations
- Dose limiting toxicities
- none across all dose levels
- Stable disease rate phase1a
- 64%
- Phase 2a preliminary data timing
- late 2026
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.